Nicotinic Acid

Abstract

Get full access to this article

View all access options for this article.

References

Jackevicius

de Leon

Krumholz

. Use of niacin in the United States and Canada. JAMA Intern Med. 2013;173(14):1379–1381.

Boden

Probstfield

Anderson

. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267.

O'Riordan

. HPS-2 THRIVE misses primary end point: no benefit of niacin/laropiprant; 2012. http://www.theheart.org/article/1490635.do. Accessed August 4, 2013.

HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279–1291.

Grundy

Cleeman

Merz

. Implications of recent clinical trials for the National cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110(2):227–239.

NLA statement on use of niacin in light of HPS2-THRIVE Presentation on March 9, 2013. https://www.lipid.org/nla/nla-statement-use-niacin-light-hps2-thrive-presentation-march-9-2013. Accessed August 4, 2013.

Whayne

Jr . Assessment of low-density lipoprotein targets. Angiology. 2013;64(6):411–416.

Canner

Berge

Wenger

. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245–1255.

Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(4):360–381.

10.

Blankenhorn

Johnson

Nessim

Azen

Sanmarco

Selzer

. The cholesterol lowering atherosclerosis study (CLAS): design, methods, and baseline results. Control Clin Trials. 1987;8(4):356–387.

11.

Blankenhorn

Nessim

Johnson

Sanmarco

Azen

Cashin-Hemphill

. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257(23):3233–3240.

12.

Lavigne

Karas

. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013;61(4):440–446.

13.

Phan

Munoz

Shadzi

. Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the familial atherosclerosis treatment study (FATS), HDL-atherosclerosis treatment study (HATS), armed forces regression study (AFREGS), and carotid plaque composition by MRI during lipid-lowering (CPC) study. Am J Cardiol. 2013;111(3):352–355.

14.

Bruckert

Labreuche

Amarenco

. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210(2):353–361.

15.

Duggal

Singh

Attri

. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2010;15(2):158–166.

16.

Digby

Ruparelia

Choudhury

. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol. 2012;32(3):582–588.

17.

Florentin

Liberopoulos

Kei

Mikhailidis

Elisaf

. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol. 2011;9(4):385–400.

18.

Schachter

. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid. Cardiovasc Drugs Ther. 2005;19(6):415–422.

19.

Erqou

Kaptoge

Perry

. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–423.

20.

Albers

Slee

O'Brien

. Relationship of apolipoproteins A-1 and B, and lipoprotein (a) to cardiovascular outcomes in the AIM-HIGH trial. J Am Coll Cardiol. 2013.

21.

Acharjee

Boden

Hartigan

. Low levels of high density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post hoc analysis from the COURAGE trial [published online August 8, 2013]. J Am Coll Cardiol. 2013.

22.

Jafri

Alsheikh-Ali

Karas

. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153(12):800–808.

23.

Kelley

. Effects of drugs on uric acid in man. Annu Rev Pharmacol. 1975;15:327–350.

24.

Niskanen

Laaksonen

Nyyssonen

. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164(14):1546–1551.